Página principal

Jonathan S. Serody md curriculum Vitae


Descargar 115.4 Kb.
Página1/3
Fecha de conversión09.07.2016
Tamaño115.4 Kb.
  1   2   3
Jonathan S. Serody MD
Curriculum Vitae
Departments of Medicine, Microbiology and Immunology

Lineberger Comprehensive Cancer Center

450 West Drive

Campus Box #7295

University of North Carolina at Chapel Hill

Chapel Hill, NC 27599-7295

Phone: 919 966-6975

FAX: 919 966-8212

e-mail: jonathan_serody@med.unc.edu
Address of Clinical Investigation:

UNC Hospitals

The University of North Carolina at Chapel Hill

101 Manning Drive

Chapel Hill, NC 27599-7600
Education:
Postdoctoral Fellowship Department of Microbiology and Immunology, University of North Carolina at Chapel Hill; mentor Jeffrey Frelinger PhD, 1990-1993

Fellowship in Clinical Bone

Marrow Transplantation: Fred Hutchinson Cancer Research Center, 1993

Fellowship in Hematology: North Carolina Memorial Hospital, July 1990-Jan 1993

Fellowship Infectious

Diseases: North Carolina Memorial Hosp, July 1989-July 1992

Residency in Medicine: North Carolina Memorial Hospital, July 1987-July 1989

Internship in Medicine: North Carolina Memorial Hospital, July 1986-July 1987

Doctor of Medicine University of Virginia Med School, July 1982-June 1986

Bachelor of Arts in Biology University of Virginia, July 1978-June 1982


Review Groups, Honors and Awards:
1987: Outstanding Intern University of North Carolina Hospitals

1992: National Research Service Award NIH

1996: KO8 Grant National Cancer Institute

1997: Ad Hoc Member Food and Drug Administration's Fever and Neutropenia Committee

1997-01: Ad Hoc Member National Cancer Institute Scientific Review Group Subcommittee D
2000-2002: Ad Hoc Member Parent Committee National Cancer Institute Scientific Review Group Subcommittee D

2001: Member Review Committee SPORE in Gyn Cancer Study Section

2001-2004: Scientific Subcommittee on Transplantation Biology American Society of Hematology

2002: Member Review Committee SPORE in Ovarian Cancer Study Section

2003: Member Review Committee SPORE in Leukemia/Lymphoma

2003: Presentation on Update in GVHD Biology American Society of Hematology Meeting

2003: Ad hoc Member Immunotherapy-Gene Therapy P01 Cluster Review NCI

2004-2007: Member SPORE Parent Committee

2005, 2006: Ad hoc Member CONC Study Section

2005: Ad hoc Member TTT Study Section

2005: Grant Review Wellcome Trust UK

2005-2012: Standing member Leukemia and Lymphoma Society TRP Grant Review

2005-present: co-leader Immunology Program Lineberger Comprehensive Cancer Center

2006: Named Elizabeth Thomas Associate Professor of Medicine, Microbiology and Immunology

2005-2012: Castle Connolly America’s Top Doctors in Cancer

2006-2012 Castle Connolly America’s Top Doctors

2006-2012: Member LRP Study Section

2007-2010: Standing Member TTT Study Section

2007-2009: Interim leader Malignant Hematology Program Lineberger Comprehensive Cancer Center

2008-present: External Advisory Board Johns Hopkins School of Medicine Breast Cancer Program

2008-2013: Scientific Subcommittee Lymphocyte Biology and Host Defense American Society of Hematology

2008-present: Hematology and Oncology Division Research Coordinator

2009-2012: CIBMTR Scientific Committee on Immunosurveillance

2010-present: Leader Malignant Hematology Program Lineberger Comprehensive Cancer Center

2010-2012: External Advisory Board Duke University Medical School Lymphoma Program

2010-present: Section Chief: Leukemia, Lymphoma and Myeloma Program Division of Medical Oncology

2010: CCSG Review Group University of Maryland Cancer Center

2011: Presidential Symposium Address American Association for Immunology

2011: ASH Basic Science Scholar Grant Review Group

2012: Chair SEP for RFA Review for NHLBI RFA “Early Phase Clinical Trials for Blood Therapies.”

2012: Invited Talk ASBMT meeting “Th17/Th22 Cells Key Actors or Bit Players in Acute GvHD.”

2012: Reviewer for NHLBI SEP ZRG1-OTC-C: SEP for TTT Members

2012: ASH Basic Science Scholar Grant Review Group

Employment History:

December 2010-present Leader Malignant Hematology Program Lineberger Cancer Center

August 2010-present Section Chief Leukemia, Lymphoma and Myeloma Service Division of Medical Oncology the University of North Carolina at Chapel Hill, NC

July 2008-present Elizabeth Thomas Professor of Medicine, Microbiology and Immunology, The University of North Carolina at Chapel Hill, NC.

November 2006 Elizabeth Thomas Endowed Associate Professor of Medicine, Microbiology and Immunology

July 2000 Associate Professor of Medicine, The University of North Carolina at Chapel Hill, NC

July 1998 Joint Appointment in Microbiology and Immunology The University of North Carolina at Chapel Hill

July 1993 – July 2000: Assistant Professor of Medicine, The University of North Carolina at Chapel Hill, NC



Bibliography

Peer Reviewed




  1. Lin K, Coghill JM, West ML, Dustin M, Bear JM, Serody JS. Intravital imaging reveals multiple mechanisms for regulatory T cell function during GVHD. Nature Medicine (under review).




  1. Dharmasiri U, Vincent, BV, , Hunsucker SA, Alatrash G, Sarantopoulos S, Serody JS, Molldrem JJ, Armistead PM. Use of RNA sequencing to identify antigens from RNA spliced variants from leukemia stem cell blasts. Science Translational Medicine (under review).




  1. Fulton LM, West ML, Coghill JM, Panoskaltsis-Mortari A, Bear JM, Foger N, Serody JS. Absence of Coronin 1A markedly attenuates GVHD by preventing lymphocyte migration and egress from secondary lymphoid tissue. Blood (under review).




  1. Coghill JM, Fowler K, West ML, Bear J, Panoskaltsis-Mortari A, Power C, Serody JS. APC interaction via CCR8 is required for the longitudinal persistence of regulatory T cells after stem cell transplantation. Blood (under revision).




  1. Wu QP, Serody JS, Van Deventer HW. Fibrocytes are critical to the recruitment of CD11b+ myeloid cells and the promotion of lung metastases. PLoS Biology (under review)




  1. Mango RL, Wu QP, West ML, Davis BK, Serody JS, van Deventer HW. CC-Chemokine Receptor 5 on Pulmonary Mesenchymal Cells Promotes Metastasis through Induction of Erythroid Differentiation Regulator 1. Clinical and Experimental Metastasis (submitted).




  1. Allen, JL, Fore MS, Wooten J, Roerhs PA, Nazmim BS, Hoffert T, Sharf A, Deal A, Armistead PM, Coghill JM, Gabriel D, Irons RN, Essenmacher A, Shea TC, Richards KL, Cutler C, Ritz J, Serody JS, Baldwin AS Jr. B cells from patients with chronic GVHD are activated and primed for survival via BAFF mediated pathways. Blood. 2012 Aug 14 [Epub ahead of print]




  1. Fedoriw Y, Samulski TD, Deal AM, Dunphy CH, Sharf A, Shea TC, Serody JS. Sarantopoulos S. Bone marrow B cell precursor number after allogeneic stem cell transplantation and GVHD development. Biology of Blood and Marrow Transplantation. 18(6): 968-973, 2012.




  1. Fulton, LM, Carlson MJ, Coghill JM, Ott LE, West ML, Panoskaltsis-Mortari A, Littman DR, Blazar BR, Serody JS. Critical role for RORt expression by CD4+ T cells in GvHD mediated by CD8+ T cells. The Journal Immunology 189(4) 1765-1772, 2012.




  1. Wood, W, Deal A, Whitley J, Sharf A, Serody J, Gabriel D, Shea T. Usefulness of the hematopoietic cell transplantation-specific comorbidity index (HCT-IC) in predicting outcomes for adolescents and young adults with hematologic malignancies undergoing allogeneic stem cell transplant. Pediatric Blood Cancer 2011 Mar 7 doi 10, 1002/pbc23057 epub ahead of print.




  1. Beaven AW, Moore DT, Sharf A, Serody JS, Shea TC, Gabriel DA. Infusional mitoxantrone plus bolus melphalan as a stem cell transplant conditioning regimen for multiple myeloma. Cancer Investigations. 29(3): 214-219, 2011.




  1. Coghill, JM, Sarantopoulos S, Moran TP, Murphy WJ, Blazar BR, Serody JS. Effector CD4+ T cells, the cytokines they generate and graft-versus-host disease: Something Old, Something New. Blood . 2011 Jan 18 [Epub ahead of print].




  1. Highfill SL, Rodriguez PC, Zhou Z, Goetz CA, Koehn BH, Veenstra RG, Taylor PA, Panoskaltsis-Mortari A, Serody JS, Munn DH, Tolar J, Ochoa AC, Blazar BR. Bone marrow myeloid-derived suppressor cells (MDSC) inhibit graft-versus-host disease (GVHD) via an arginase-1 dependent mechanism that is upregulated by IL-13. Blood 116(25): 5738-5747, 2010.




  1. Carlson M, Fulton, L, Coghill JM, West MJ, Panoskaltsis-Mortari, A, Wan Y, Tedder T, Blazar BR, Serody JS. L-selectin is not absolutely required for regulatory T cell function in GVHD. American Journal of Transplantation, 10(12): 2596-2603, 2010.




  1. *Van Deventer H, *Burgents JE, Wu QP, Woodford RM, Brickey WJ, Allen IC, Tekippe EM, **Serody JS, **Ting JPY. The inflammasome component, NLRP3, impairs antitumor vaccination by enhancing accumulation of peritumoral myeloid derived suppressor cells. Cancer Research. 70(24): 10161-10169, 2010.* and ** equally contributed to work




  1. Wood WA, Whitley J, Moore D, Sharf A, Iron R, Rao K, Serody J, Gabriel D, Shea T. Chemomobilization with etoposide is highly effective in patients with myeloma and overcomes the effects of age and prior therapy. Biology of Blood and Marrow Transplantation. 17(1): 141-146, 2011.




  1. Coghill JM, Carlson MJ, Panoskaltsis-Mortari A, West ML, Burgents JE, Blazar BR, Serody JS. Separation of graft-versus-host disease from graft-versus-leukemia responses by targeting C-C chemokine receptor 7 on donor T cells. Blood 115(23): 4914-4922, 2010 (Inside Blood Comment).




  1. Burgents, JE, Moran TM, Collier ML, West MJ, Davis NL, Johnston RE, Serody JS. The immunosuppressive tumor environment is the main impediment to successful vaccination in neu transgenic mice. J Immunotherapy 33(5): 482-491, 2010.




  1. Wood, W, Garg, S, Adamus G, Gabriel D, Shea T, Serody, J. Alloimmune Retinopathy associated with antibodies to transducin-α as a complication of chronic GVHD. Biol of Blood and Marrow Transplantation DOI: 10:1016/j 06.012, 2009..




  1. Shea TC, Beaven AW, Moore DT, Serody JS, Gabriel DA, Chao NK, Gockerman J, Lindley C, Garcia R, Schell M and Rizzieri DA.Sequential high-dose ifosfamide, carboplastin and etoposide with ritucimab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival. Leukemia & Lymphoma 8(1-8) (epub ahead of print, 2009).




  1. Rao, KV, Buie LW, Shea T, Gabriel DA, Comeau T, Irons R, Serody J, Eron B. Intravesicular cidofovir for the management of BK virus-associated cystitis. Biol Blood Marrow Transplant 15(3): 391-392, 2009.




  1. O’Shaunessey MJ, Vogtenhuber C, Sun K, Sitcheran R, Baldwin AS, Murphy WJ, Dang L, Jaffee B, Palmer E, Serody JS, Blazar BR..Ex vivo inhibition of NF-kappaB signaling in alloreactive T-cells prevents graft-versus-host disease. American Journal of Transplantation 9(3): 452-462, 2009.




  1. Carlson, MJ, West M, Panoskaltsis-Mortari, A, Blazar BR. Serody JS. In vivo generated Th17 cells mediate lethal GVHD with severe cutaneous and pulmonary pathology. Blood113(6): 1365-1374, 2009.




  1. Taylor PA, Ehrhardt MJ, Lees CJ, Panoskaltsis-Mortari A, Krieg AM, Sharpe AH, Murphy WJ, Serody JS, Hemmi H, Akira S, Levy RB, Blazar BR. TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. Blood 112(8): 3508-3516, 2008.




  1. Coghill, J, Carlson M, Moran TJ and Serody JS. The biology and therapeutic potential of natural regulatory T-cells in the bone marrow transplant setting. Leukemia and Lymphoma July 25, 1-10, 2008.




  1. van Deventer HW, Ping QW, Bergstralh DT, Davis BK, O'Connor BP, Ting JPY and Serody JS. C-C Chemokine Receptor 5 on Pulmonary Fibrocytes Facilitates Migration and Promotes Metastasis via Matrix Metalloproteinase 9. American Journal of Pathology, 173(1): 253-264, 2008.




  1. Petermann KB, Rozenberg GI, Zedek D, Groben P, McKinnon KP, Buehler C, Kim W, Shields JM, Bear JE, Thomas NE, Serody JS, Sharpless NE. Erk activation induces CD200 expression and T cell suppression in melanoma. Journal of Clinical Investigation 117(12): 3922-3929, 2007.




  1. Moran TP, Burgents JE, Long B, Ferrer I, Jaffee EM, Tisch R, Johnston RE, Serody JS. Alphaviral-vector transduced dendritic cells are successful therapeutic vaccines against Neu-expressing tumors. Vaccine 25(36):6604-6612, 2007.




  1. Taylor PA, Ehrhardt MJ, Lees CJ, Tolar J, Weigel BJ, Panoskaltsis-Mortari A, Serody JS, Binkmann V, Blazar BR. Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of GVHD. Blood 110(9): 3480-3488, 2007




  1. Serody J. The CCR deletion mutation and graft-versus-host disease. Haematologica. 91(12): 1586A, 2006




  1. Taylor PA Ehrhardt MJ, Roforth MM, Swedin JM, Panoskaltsis-Mortari A, Serody JS, Blazar BR. Preformed antibody, not primed T cells, is the initial and major barrier to bone amrrow engraftment in allosensitized recipients. Blood 109(3): 1307-1315, 2007.




  1. Gilman A and Serody JS. Biology and Management of chronic GVHD. Seminars in Hematology 43(1): 70-80, 2006.




  1. Gabriel DA, Shea TC, Serody JS, Moore, DT, Kirby SL, Harvey, D, Bigelow SH, and Krasnov C. Cytoprotection by Amifostine (Ethyol®) During Autologous Stem Cell Transplantation for Advanced Refractory Hematologic Malignancies. Biology of Blood and Marrow Transplantation 11(12): 1022-1030, 2005.




  1. Taylor, PA, Panoskaltsis-Mortari A, Freeman GJ, Sharpe, AH, Noelle RJ, Rudensky AY, Mak TW, Serody JS, Blazar BR. Targeting of inducible costimulator expressed on alloreactive T cells down regulates graft-versus-host disease and facilitates engraftment of allogeneic bone marrow. Blood. 105(8): 3372-3380, 2005.




  1. Moran, T, Collier, M, McKinnon, KP, Davis NL, Johnston RE, Serody JS. A novel viral system for generating antigen-specific T cells. Journal of Immunology. 175(3): 3431-3438, 2005.




  1. Wysocki, C, Panoskaltisis-Mortari, A, Blazar BR, Serody JS. Leukocyte migration and GVHD. Blood. 105(11): 4191-4199, 2005.




  1. Wysocki C, McKinnon KM, Raimondo C, Lee H, Su, L, Blazar BR, Serody JS. Critical role for CCR5 in the function of CD4CD25+ regulatory T cells during acute GVHD. Blood 2005 July 7 106(9): 3300-3307, 2005.




  1. van Deventer H, O’Connor Jr W, Brickey WJ, Aris RM, Ting JPY, Serody JS. Critical role for stromal cell production of CCR5 in pulmonary metastasis. Cancer Research 65: 3374-3379, 2005.




  1. Hildebrandt, GC, Olkiewicz, KM, Choi S, Corrion LA, Clouthier S, Liu C, Serody JS, and Cooke KR. Donor T cell production of RANTES significantly contributes to the development of idiopathic pneumonia syndrome after allogeneic stem cell transplantation. Blood. 105:3372-3380, 2005. (Plenary Manuscript)




  1. Blazar BR, Levy RB, Mak TW, Mortari-Panoskaltsis A, Muta, H, Jones, M, Roskos, M, Serody JS, Yagita, H, Podack ER, and Taylor PA. CD30/CD30 ligand (CD153) interaction regulates CD4+ T cell mediated graft-versus-host disease. Journal of Immunology. 173:2933-2941, 2004.




  1. Taylor, P, Panoskaltsis-Mortari, A, Wilson, J, Lucas, P, Gress, R, Levine, B, June, C, Serody JS, Blazar, BR. L-selectin but not the L-selectin lo CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood 104, 3804-12, 2004.




  1. Sun, K, Welniak LA, Panoskaltsis-Mortari, A, O’Shaughnessy, MJ, Liu, H, Barro I, Riordan, W, Sticheran R, Wysocki C, Serody JS, Blazar BR, Sayers, TJ, and Murphy WJ. Inhibition of acute GVHD with promotion of anti-tumor effects by the proteasome inhibitor, bortezemib, after allogeneic bone marrow transplantation. Proceedings of the National Academy of Science USA. 101(21): 8120-8125, 2004.




  1. Sauer MG, Ericson ME, Weigel BJ, Herron MJ, Panoskaltsis-Mortari A, Kren BT, Levine BL, Serody JS, June CH, Taylor PA, Blazar BR. A novel system for simultaneous in vivo tracking and biological assessment of leukemia cells and ex vivo generated leukemia-reactive cytotoxic T cells. Cancer Research 64(11): 3914-3921, 2004




  1. Wysocki, C, Burkett SE, McKinnon, K Kirby, SL, Luster, A, Blazar BR and Serody JS. Differential role of CCR5 on donor T cells during GVHD based on pretransplant conditioning. Journal of Immunology 173(2)845-854, 2004




  1. Dees, EC, McKinnon,van Deventer H, Chwastiak K, Sparks, S, Myers, M, Collins, E, Frelinger J, Collichio, F, Carey, L, Brecher, M, Earp, HS, Graham, M, and Serody JS. Dendritic cells can be rapidly and effectively expanded in patients with metastatic breast cancer. Cancer Immunology Immunotherapy. 53(9): 777-785, 2004.




  1. Panoskaltsis-Mortari, A, Price, A, Hermanson, J, Taras, E, Lees, E, Serody JS, Blazar, BR. In vivo imaging of graft-versus-host disease in mice. Blood 103:3590-3598, 2004.




  1. Shea, TC, Brunner, R, Wiley, JM, Serody JS, Sailer, S, Gabriel DA, Capel E, Moore, D, Dent, G, Bentley, S and Brecher, M. An Expanded Phase I Trial of Cyclophosphamide, Etoposide, and Carboplatin plus Total Body Irradiation with Autologous Marrow or Stem Cell Support for Patients with Hematologic Malignancies. Biology of Blood and Marrow Transplantation 9(7):443-452, 2003.




  1. Lindley, C, McCune, JS, Shord, S, Decker, J., Harvey, D., Kirby, SL, Gabriel DA, Petros, WP, Shea TC, Serody JS, and Wiley JM. Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: Assessment of a test dose and first dose strategy. Anti-Cancer Drugs. 15(5): 453-459, 2004.




  1. Mortari-Panoskaltsis, A, Hermansen, JR, Taras, E, Wangensteen OD, Serody JS, and Blazar BR. Acceleration of idiopathic pneumonia syndrome (IPS) in the absence of donor MIP-1 (CCL3) after allogeneic BMT in mice. Blood. 101: 3714-21, 2003.




  1. van Deventer, Serody, JS, McKinnon, KP, Clements, C, Brickey, WJ, Ting JPY. Transfection of Macrophage inflammatory protein 1a into B16-F10 melanoma cells inhibits growth of pulmonary metastases but not subcutaneous tumors. Journal of Immunology 169:1634-1639, 2002.




  1. Ng-Cashin, J, Kuhns, JJ, Burkett, S.E., Powderly, JD, Craven, RR, van Deventer, HW, Kirby, SL and Serody JS. Host absence of CCR5 potentiates DC vaccination. Journal of Immunology. 170: 4201-08, 2003.




  1. Serody JS, Burkett S, Mortari-Panoskaltsis A., Ng-Cashin J, McMahon E., Matshushima G, Lira SA, Cook DN, Blazar BR. T lymphocyte production of MIP-1( is critical to the recruitment of CD8+ T cells to the liver, lung and spleen during graft-versus-host disease. Blood. 96: 2973, 2000.




  1. Serody, JS. Sparks, S Yin, Y., Capel E., Bigelow, S. Kirby, SL. Gabriel, D. Wiley, JM., Brecher, M., Schell, M., Folds, F. and Shea, TC. Comparison of g-CSF-mobilized peripheral blood progenitor cells and g-CSF-stimulated bone marrow as a source of stem cells in HLA-matched sibling transplantation. Biology of Blood and Marrow Transplantation. 6:434-440, 2000




  1. Serody JS, Berrey MM, Albritton K, Schell M, O'Brien S, Weber DJ, Powell E, Gabriel DA, Wiley JH, Gilligan P, Shea TC. Utility of obtaining blood cultures during febrile leukopenia in bone marrow transplant recipients. Bone Marrow Transplantation. 26(5): 533-39, 2000.




  1. Serody JS, Collins EJ, Tisch R, Kuhns JJ, Frelinger JA. Dendritic cell vaccination is dependent on the antigen and route and frequency of administration. Journal of Immunology 164:4961-4967, 2000




  1. Cook D. N., O Smithies, RM Strieter, JA Frelinger, and JS Serody. CD8+ T cells are in vivo relevant source of MIP-1a. Journal of Immunology 162:5423-5428, 1999.




  1. Serody JS, Cook DN, Kirby SL, Reap E., Shea TC, and Frelinger JA. Murine T lymphocytes incapable of producing MIP-1( are impaired in causing GVHD across a class I but not class II MHC barrier. Blood 93:43-50, 1999.




  1. Serody JS, Brecher ME, Dent G, Bentley SA, Frelinger JA, Shea TC. A method for the production of CD4 positive CML-specific allogeneic T lymphocytes, Cancer Research 57:1547-1553, 1997.




  1. Bentley SA, Brecher ME, Powell E, Serody JS, Wiley JM, Shea TC. Late engraftment failure after Marrow ablation and autologous hematopoietic reconstitution: Differences between peripheral blood stem cell and bone marrow recipients. Bone Marrow Transplantation, 19:(6), 557-563 1997.




  1. Serody J, Poston RM, Weinstock D, Kurlander RJ, Frelinger JA. CD4+ cytolytic effectors are inefficient in the clearance of Listeria monocytogenes. Immunology 88:544-550, 1996.




  1. Bandarenko NB, Brecher ME, Owen H, Wiley J, Shea T, Serody J. Thrombocytopenia in allogeneic peripheral blood stem cell collections. Transfusion, 36:7, p 668-669, 1996.




  1. Rex JH, Benrett JE, Sugar AM, Pappas PG, Serody JS, Edwards, JED, and Washburn RG. Intravascular catheter exchanges and the duration of candidemia. Clinical Infectious Disease. 21:994-6, 1995.




  1. Britigan BE, Serody JS, Rosen GM and Cohen MS. Lactoferrin, as an anti inflammatory protein in professional phagocytic cells. Advances in Experimental Medicine & Biology. 357: 143-156, 1994.




  1. Serody JS, Mill MR, Detterbeck FC, Harris DT and Cohen MS. Blastomycosis in transplant patents: Report of a case and review of the literature. Clinical Infectious Disease. 16(1):54-8, 1993.




  1. Cohen MS, Mao J, Rasmussen GH, Serody JS and Britigan BE. Interaction of lactoferrin and lipopolysaccharide: Effects of lactoferrin antioxidant activity and priming of human neutrophils for formation of OH. Journal of Infectious Disease. 166(6):1375-9, 1992




  1. Britigan BE, Serody JS, Hayek MB, Charniga LM and Cohen MS. Receptor-mediated uptake of lactoferrin by mononuclear phagocytes inhibits their ability to form hydroxyl radical. Journal of Immunology 147:4271-4277, 1991.

Non Peer Reviewed Manuscripts:




  1. Serody JS. Bacterial sepsis and GI tract GVHD: More commensal than you think. Blood 120(1): 6-7, 2012.




  1. Serody JS, Hill GR. The IL-17 differentiation pathway and its role in transplant outcome. Biology of Blood and Marrow Transplantation. 1 Suppl) S56-61, 2012



  1   2   3


La base de datos está protegida por derechos de autor ©espanito.com 2016
enviar mensaje